TGFBR1 and type 2 diabetes mellitus: We therefore suggest that screening for compounds that inhibit Alk5 signaling specifically in β cells may yield compounds that in combination with traditional blood-glucose lowering medicines will delay, prevent, or perhaps restore the loss of healthy, mature β cell function in T2D patients.